| 臺大學術典藏 |
2022-05-14T23:35:11Z |
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
|
HSIANG-FONG KAO; BIN-CHI LIAO; Huang, Yen Lin; HUAI-CHENG HUANG; Chun-Nan Chen; TSENG-CHENG CHEN; Hong, Yuan Jing; Chan, Ching Yi; JEAN-SAN CHIA; Hong, Ruey Long |
| 臺大學術典藏 |
2021-09-14T23:19:15Z |
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
|
BIN-CHI LIAO; Chih-Hsin Yang, James |
| 臺大學術典藏 |
2021-08-20T08:00:44Z |
Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study
|
BIN-CHI LIAO; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
|
BIN-CHI LIAO; Lin C.C.; Shih J.Y.; Yang J.C.H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
BIN-CHI LIAO; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:42Z |
Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice
|
Liang Y.-H.; Shao Y.-Y.; BIN-CHI LIAO; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-20T08:00:42Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
BIN-CHI LIAO; Lee J.-H.; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:42Z |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
BIN-CHI LIAO; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis
|
Guo J.-C.; Chang C.-C.; Yang C.-Y.; BIN-CHI LIAO; Liau J.-Y.; Chang C.-H.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
BIN-CHI LIAO; Lin C.-C.; Lee J.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
BIN-CHI LIAO; Lin C.-C.; Lee J.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
BIN-CHI LIAO; Bai Y.-Y.; Lee J.-H.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; BIN-CHI LIAO; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:39Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:39Z |
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:39Z |
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
|
BIN-CHI LIAO; Griesing S.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:38Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; BIN-CHI LIAO; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:38Z |
Exon 16�VSkipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M�VPositive Non�VSmall Cell Lung Cancer
|
Hsu C.-C.; BIN-CHI LIAO; Liao W.-Y.; Markovets A.; Stetson D.; Thress K.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:38Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:37Z |
CD73 Is regulated by the EGFR-ERK signaling pathway in non-small cell lung cancer
|
Griesing S.; BIN-CHI LIAO; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:37Z |
Lung Cancer in Republic of China
|
Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; Yang J.C.-H.; BIN-CHI LIAO; Hsia T.-C.; Chen Y.-M. |
| 臺大學術典藏 |
2021-08-15T00:07:58Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
BIN-CHI LIAO; Hsu, Wei Hsun; Lee, Jih Hsiang; Yang, Ching Yao; TZU-HSIU TSAI; WEI-YU LIAO; CHAO-CHI HO; Chia-Chi Lin; JIN-YUAN SHIH; CHONG-JEN YU; Soo, Ross A.; CHIH-HSIN YANG |
